Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...
FDA has started its review of an autoinjector version of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to be dosed at home. Join the conversation, on Tuesday 28th January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback